A Multicenter, Open-Label Trial to Evaluate the Overall Performance of the Zalviso System (Sufentanil Sublingual Tablet System) 15 mcg
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Sufentanil (Primary)
- Indications Postoperative pain
- Focus Registrational; Therapeutic Use
- Sponsors AcelRx Pharmaceuticals
- 01 Aug 2017 According to an AcelRx Pharmaceuticals media release, the company intends to submit results from this trial together with results of earlier phase 3 studies (IAP309, IAP310 and IAP311) as part of resubmission of a New Drug Application to the FDA by the end of 2017.
- 01 Aug 2017 Primary endpoint (Device Functionality) has been met, according to results published in an AcelRx Pharmaceuticals Media Release.
- 01 Aug 2017 Status changed from active, no longer recruiting to completed, according an AcelRx Pharmaceuticals Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History